

# UNIVERSITY OF MINNESOTA

*Twin Cities Campus*

*Research Subjects' Protection Programs*

*Institutional Review Board: Human Subjects Committee (IRB)  
Institutional Animal Care and Use Committee (IACUC)*

*Mayo Mail Code 820  
D-528 Mayo Memorial Building  
420 Delaware Street S.E.  
Minneapolis, MN 55455*

July 25, 2002

*612-626-5654  
Fax: 612-626-6061  
irb@umn.edu  
iacuc@umn.edu  
[http://www.research.umn.edu/  
subjects.htm](http://www.research.umn.edu/subjects.htm)*

Marilyn Carroll  
Psychiatry  
MMC 392  
Minneapolis Campus

Re: "Primate Model of Drug Abuse: Intervention Strategies"  
Animal Subjects Code Number: **0112A14081**

Dear Dr. Carroll:

The Institutional Animal Care and Use Committee (IACUC) has received your response to its stipulations. Since this information satisfies the requirement set by the IACUC, final approval for the change in protocol described in your May 14, 2002 letter and amended with your July 17, 2002 letter is noted in our files.

You are approved for the transfer of 18 Class A Monkeys.

Upon receipt of this letter you may institute the changes. If you have any questions, please call me at (612) 626-5654.

Sincerely,



Michelle Dawson  
IACUC Manager

MD/ejv

DEC 1 2004 PM 4:27

# UNIVERSITY OF MINNESOTA

Twin Cities Campus

*Division of Neuroscience Research in Psychiatry  
Department of Psychiatry  
Medical School*

*Box 392 Mayo Memorial Building  
420 Delaware Street S.E.  
Minneapolis, MN 55455  
612-626-4034  
Fax: 612-624-8935*

DEC 1 2004 PM 4:27

July 17, 2002

Michelle Dawson  
Mayo Mail Code 820  
CAMPUS MAIL

Re: "Primate Model of Drug Abuse: Intervention Strategies"

Animal Subjects Code Number: 0112A14081

Dear Ms. Dawson"

This letter is in response to your letter of June 13, 2002 regarding two questions on the addendum to this protocol.

1. Explain how it was determined that 18 is the appropriate number of animals.

There are three groups of six to be studied, and previous statistical analyses and power calculations based on similar studies indicate that at least six animals per group are necessary to achieve statistical significance

2. Indicate methods used to search for alternatives.

We have searched on Medline and Pubmed databases to find alternatives. Human research is the only alternative for this type of imaging study, but we are not able to control the drug dose consumed in humans and we aren't able to do the long term measures (six months) that we are proposing. Other studies of this type have not been conducted in rhesus monkeys.

I hope this answers the questions the committee had to the requested addition of MRI imaging to the approved behavioral protocol.

Sincerely,

Marilyn E. Carroll, Ph.D.  
Professor of Psychiatry and Neuroscience  
Department of Psychiatry  
Mayo Box 392  
Minneapolis, MN 55455  
Tel: (612) 626-6289  
Fax: (612) 624-8935  
e-mail: mcarroll@umn.edu

# UNIVERSITY OF MINNESOTA

Twin Cities Campus

Research Subjects' Protection Programs

Institutional Review Board: Human Subjects Committee (IRB)  
Institutional Animal Care and Use Committee (IACUC)

Mayo Mail Code 820  
D-528 Mayo Memorial Building  
420 Delaware Street S.E.  
Minneapolis, MN 55455

612-626-5654  
Fax: 612-626-6061  
irb@umn.edu  
iacuc@umn.edu  
<http://www.research.umn.edu/subjects.htm>

June 13, 2002

Marilyn Carroll  
Psychiatry  
MMC 392  
Minneapolis Campus

DEC 12 2004 9:42:27

Re: "Primate Model of Drug Abuse: Intervention Strategies"  
Animal Subjects Code Number: 0112A14081

Dear Dr. Carroll:

At its meeting on June 11, 2002 the Institutional Animal Care and Use Committee (IACUC) reviewed the change in protocol described in your letter dated May 14, 2002, for the referenced study. The following stipulations must be satisfied before approval for the change can be granted.

1. Please explain how you determined that 18 is the appropriate number of animals for this change.
2. Please indicate methods used to search for alternatives.

(See <http://www.ahc.umn.edu/rar/ethics.html#Alternatives> for resources to assist in the search)

Please return your response to these questions to this office as soon as possible. We will process the final approval for this protocol as quickly as possible at that time. If you have any questions, please call the IACUC office at (612) 626-5654.

Sincerely,

  
Michelle Dawson  
IACUC Manager

MD/ki

# UNIVERSITY OF MINNESOTA

*Twin Cities Campus*

*Division of Neuroscience Research in Psychiatry  
Department of Psychiatry  
Medical School*

*Mayo Mail Code 392  
420 Delaware Street S.E.  
Minneapolis, MN 55455  
612-626-4034  
Fax: 612-624-8935*

May 14, 2002

Michelle Dawson  
IACUC Manager  
Box 820 Mayo  
University of Minnesota  
Campus Mail

RE: "Primate Model of Drug Abuse: Intervention Strategies"  
Animal Subject Code Number 0112A14081

Dear Michelle:

This is an addendum to the above referenced protocol. I am writing to request the temporary transfer of up to 18 rhesus monkeys in small groups of 1-6, from

In collaboration with Drs. Kamil Ugerbil, Itamar Ronen, Charles Schulz and Kelvin Lim, I would like to obtain brain images of these monkeys. Some will have had experience with drugs such as cocaine or phencyclidine (PCP), and others will be drug naïve. We are interested in gaining additional information regarding temporary and long-term changes in brain structures due to their history of drug self-administration.

The monkeys will be anesthetized with ketamine/xylazine (15 mg/kg and 0.5 mg/kg i.m.), Upon arrival, they will be transferred to standard individual monkey cages in the animal room and allowed to acclimate for at least 24 hours before MRI imaging begins. They will have free access to food and water until 5 p.m. the evening before they are imaged in the MRI scanner. Food and water access will be resumed as soon as the effects of anesthesia have dissipated.

On the day they are imaged, monkeys will be anesthetized using an initial dose of ketamine/xylazine (15 mg/kg i.m. and 0.5 mg/kg i.m.) and supplemented with sodium pentobarbital (1-2 mg/kg/hr i.v.). If experimentally necessary, we will intubate animals and place them on a respiratory assist machine. Anesthesia in intubated animals will be maintained with isoflurane (1.0% in N<sub>2</sub>O/O<sub>2</sub>), rather than pentobarbital. Monkeys will be placed either in an MR compatible stereotaxic frame, or in a specially designed primate chair. Either holding device will provide head restraint and cushioning at pressure points. A rectal temperature probe will be inserted, and tubing containing water heated by a temperature feedback device will be used to provide regulated warmth. Foam earplugs 10dB are used to minimize auditory stimulation due to noise generated by the RF sequence. We expect each procedure will last between 4-6 hours. At the end of the procedure monkeys will be returned to their cage and observed until they recover from anesthesia (are able to hold their head up). Each monkey will undergo no more than one procedure per week.

This model has previously been used with rhesus macaques as indicated in the following references, and we are not aware of any adverse effects of the magnetic imaging procedure.



Leopold, D. A., Plettenberg, H.K. & Logothetis, N.K. Visual processing in the katamine-anesthetized monkey: Optokinetic and blood oxygenation level-dependent responses. *Exp Brain Res* 143, 359-72 (2002).

Disbrow, E. A., Slutsky, D.A., Roberts, T.P. & Krubitzer, L.A. Functional MRI at 1.5 tesla: a comparison of the blood oxygenation level-dependent signal and electrophysiology. *Proc Natl Acad Sci U S A* 97, 9718-23 (2000).

The total duration of this addendum to the behavioral experiments that we conduct in would be no more than six months, and it can be as short as a few days. After the imaging data are obtained, we will return the monkeys to according to the transfer procedures we used to get them to the ketamine/xylazine anesthesia, transfer cages, , and placement in their standard cages. The transfer process should take no more than 30 minutes, and the anesthesia used on them for transfer is already used for TB testing and veterinary exams, and it is well-tolerated.

Please let me know if the IACUC has any questions or needs additional information regarding this addendum.

Sincerely,

Marilyn E. Carroll, Ph.D.  
Professor of Psychiatry and Neuroscience  
Department of Psychiatry  
Box 392 Mayo  
Minneapolis, MN 55455  
Tel: (612) 626-6289  
Fax: (612) 624-8935  
E-mail [mcarroll@umn.edu](mailto:mcarroll@umn.edu)

## Appendix C

### Controlled Substances

**Controlled Substances:** Contact the Office of Regulatory Affairs at 612-625-9624 for controlled substances registration information or for guidance completing this section. Visit the web at <http://www.dehs.umn.edu/ihsd/controlledsubs/> for more help.

Name of DEA registrant	Marilyn E. Carroll
Name of MNBP registrant	Marilyn E. Carroll
MNBP number (7 digits)	

Name of controlled drug or substance	DEA Drug Schedule (I, II, III)	Dosage	Do you use a controlled substance safe?	Do you maintain complete inventory and disposition use records?
Heroin	I	0.06, 0.12, 0.25, 0.5, 1.0 mg/kg	yes	yes
Cocaine	II	10 mg/kg	yes	yes
Methamphetamine	II	1 mg/kg	yes	yes
Phencyclidine	II	0.06, 0.12, 0.25, 0.5, 1.0 mg/ml	yes	yes
Pentobarbital	II	100 mg/kg	yes	yes
Methadone	II	0.8 mg/ml	yes	yes
Ketamine	III	10 mg/kg	yes	yes
Baclofen	IV	0.5, 1.25, 2.5 mg/kg	yes	yes
Bremazocine	IV	0.32, 1, 2.5 mg/kg	yes	yes
SR-141716A (CB1 antagonist)	not scheduled	0.3 - 3 mg/kg	yes	yes

relationships. When the price of drug is increased, consumption decreases. When an alternative drug or substance is available at a fixed-price, and its consumption increases as the demand for the original substance decreases (due to increased price), the second substance functions as a substitute. Substances that will be self-administered and also tested as substitutes for other drugs will be smoked cocaine and heroin, and orally-delivered ethanol, PCP and saccharin. Ethanol will be used in this experiment because it is often used with other drugs and substituted when a user terminates use of another drug (NIDA, 1991).

Six male rhesus monkeys (Group 3) will be used in this experiment. *The lab is shifting from all males to equal numbers of males and females. However, there will still be 6 more males than females, and not enough females to examine sex differences in each of the proposed experiments. Data from this group will be used to compare behavioral economic data to that obtained with males in previous studies.* They will have had recent experience with short and long periods of drug access [Experiment a(2a)] and acquisition of methadone self-administration [Experiment a(2b)] as shown in Table 9. The experimental design is outlined in Table 5. There are 20 conditions in which one drug or saccharin will be tested as a substitute for another drug or saccharin. A demand curve will be generated by varying the FR for the self-administered drug, and the potential substitute drug or saccharin will be available at a fixed FR. The fixed FR will be 8 for ethanol, 16 for PCP and saccharin and 128 for cocaine and heroin. The 20 conditions will be run in nonsystematic order and counterbalanced across monkeys.

Dependent Measures and Data Analyses: Demand curves will be constructed as described for Experiment a(1b) using the same dependent measures, for the substances with a varied FR. Cross-price elasticity regression coefficients will also be obtained for the substances with fixed FR values. When plotted on log-log coordinates a cross-price elasticity coefficient  $\geq 0.2$  will be defined as a substitute,  $\leq -0.2$  will be defined as a complement, and between 0.2 and -0.2 will be defined as an independent. Point-by-point slopes as well as the overall best-fitting line will be calculated. Changes in consumption across FR values will be analyzed by repeated measures ANOVAs, and Bonferroni-corrected matched pairs t-tests will be used to further analyze overall main effects.

Table 5 Substitution of Drug and Nondrug Reinforcers

Exp b(1b)

Varied FR (4, 8, 16, 32, 64, 128) For:		Fixed FR (16) for Concurrent:				
		Cocaine	Ethanol	Heroin	PCP	Saccharin
✓	Cocaine	○	○	○	○	○
	Ethanol	○	○	○	○	○
	Heroin	○	○	○	○	○
✓	PCP	○	○	○	○	○
	Saccharin	○	○	○	○	○

6 male monkeys will be used in all 20 conditions indicated by open blocks

### b(2) Pharmacological interventions

b(2a) Effects of baclofen on the demand for self-administered cocaine, heroin, PCP, food and saccharin: Effect of sex. The purpose of this experiment is to compare the effects of baclofen, a GABA<sub>B</sub> receptor agonist, on behavior maintained by drug and nondrug reinforcers in male and female rhesus monkeys. This work will extend the findings that baclofen decreases i.v. cocaine self-administration in rats (Campbell and Carroll, 2000a; Campbell et al., 2000a) and cocaine use and craving in humans (Ling et al., 1998) to monkeys, other drugs of abuse, and other routes of administration. It is hypothesized that baclofen will suppress drug- and saccharin-maintained behavior, but it will have a minimal effect on food-maintained behavior. *Baclofen currently appears to be a promising treatment drug, however, another medication may be substituted if one that is more selective for suppressing drug self-administration and has minimal side effects is available. A cannabinoid CB1 antagonist (SR-141716A) will also be used.*

Seven male and 7 female rhesus monkeys (Group 2) will be trained to self-administer smoked cocaine base (1 mg/kg) and heroin (0.1 mg/kg), and orally-delivered PCP (0.25 mg/ml), food (10 g) and saccharin (0.3 % w/v) according to procedures described in the General Methods section. Food- and saccharin-maintained behavior will be examined as controls for drug-selective effects. While each substance is available for self-administration, 3 doses of baclofen (0.5, 1.25 and 2.5 mg/kg) and saline will be administered i.m. 15 min prior to the 3-hr self-administration session for 21 consecutive days. *If increasing or decreasing trends in the suppression of drug self-administration occur within the 21-day treatment period, the length of treatment will be extended to more closely approximate the human situation and fully characterize the time course of treatment effects. If there are no changes in the magnitude of the treatment effect over the 21 days using several doses and under different self-administration conditions, the duration of treatment may be shortened to 5-10 days using the last 5 days as a*

DEC 1 2004 PM 4:27

sample of stable behavior. Three concentrations (PCP) or doses (cocaine, heroin) of each drug will also be tested at one (optimal) dose for the treatment drug. The order of testing the self-administered substances, and baclofen doses will be counterbalanced across monkeys. The dose or concentration used for the self-administered drug will be selected from the middle of the range of effective reinforcing doses/concentrations. The baclofen doses were based on the rat and human studies cited above. The FR value will be held constant at 16 for food and drinking and 128 for smoking, values that are sensitive to behavioral and pharmacological treatments. The left side of the shaded portion of Table 6 illustrates the experimental design. Under each baclofen dose condition, blood samples will be taken during inter-session to compare effects on the self-administered drug in males vs. females. Females may be more or less sensitive to baclofen than males. Thus, it is necessary to compare dose response curves across males and females and to observe any physical signs indicating side effects. The CO<sub>2</sub> antagonist, SR-141716A will also be used in male and female monkeys, at 3 doses 0.3, 1 and 3 mg/kg and the 3.0 mg/kg dose will be used when the demand curve (x) is obtained.

Table 6 Pharmacological Interventions

Self-administered substance	Dose	Exp b(2a)		b(2b)		Exp b(2a)		b(2b)	
		Dose effect, saline + 3 doses				Demand curve FR 4, 8, 16, 32, 64, 128			
		-- Pretreatment Drug --				* -- Pretreatment Drug --			
		Baclofen		Bremazocine		Baclofen		Bremazocine	
		Female	Male	Female	Male	Female	Male	Female	Male
Cocaine	Low								
	Med								
	High								
Heroin	Low								
	Med								
	High								
PCP	Low								
	Med								
	High								
Saccharin									
Food									

In the second phase of this experiment the effect of baclofen on the demand for cocaine, heroin, PCP, food and saccharin will be evaluated by using an effective dose of baclofen that was determined by the dose effect function, and then varying the FR for the self-administered substance to construct demand curves. The demand functions will be obtained according to the procedures described in General Methods. The drug dose and amount of food or saccharin will be selected such that the demand curves (e.g., P<sub>max</sub>) are similar for the 5 substances. Baclofen will be administered at each of the FR requirements for at least 5 days or until behavior stabilizes, and the preceding 5-day period will serve as a nontreatment control. FR values will be tested in nonsystematic order and counterbalanced across monkeys. The left side of the unshaded portion of Table 6 summarizes the design of Experiment b(2a).

Dependent Measures and Data analysis. Responses, deliveries, volume, and mg/kg consumed from the 5 days of stable behavior before treatment will be compared to the last 5 days of baclofen treatment. Behavior will be allowed to stabilize for 5 consecutive days before changes in the experimental conditions are made. Stability is defined as no steadily increasing or decreasing trend in the dependent measure over 5 days. Dose effect comparisons will be made using repeated measures (treatment dose, and/or self-administration dose) ANOVAs and subsequent comparisons as described for Experiment a(2a). Similarly the demand curve analysis will be conducted as described for Experiment a(1b).

b(2b) Effects of bremazocine on the demand for self-administered cocaine, heroin, PCP, food and saccharin: Effect of sex. The goals of this experiment are to compare the effects of bremazocine, a kappa receptor agonist, on behavior maintained by drug and nondrug reinforcers in male and female rhesus monkeys. Preliminary data (Study 3) indicate that bremazocine dose-dependently reduces cocaine, PCP and saccharin self-administration in male monkeys, but it has less of an effect on ethanol- and food-maintained behavior. This experiment will extend the research to other drugs (e.g., heroin), routes of administration (smoking), and it will determine whether there are sex differences in medication effects.

The design of this experiment is summarized in Table 6 (right side of shaded portion), and the procedure is similar to that described for Experiment b(2a). Seven male and 7 female rhesus monkeys (Group 2) will be trained to self-administer smoked cocaine base (1 mg/ml) and heroin (0.1 mg/ml) and orally-delivered PCP (0.25 mg/ml), saccharin (0.3% w/v) and food with water concurrently available as described in the General Methods section. While each substance is available for self-administration, 3 doses of bremazocine (0.32, 1 or 2.5 mg/kg) and saline will be administered i.m. 15 min prior to the 3-hr self-administration session for 21 consecutive days. As in the case



# UNIVERSITY OF MINNESOTA

Twin Cities Campus

Division of Neuroscience Research in Psychiatry  
Department of Psychiatry  
Medical School

Mayo Mail Code 392  
420 Delaware Street S.E.  
Minneapolis, MN 55455  
612-626-4034  
Fax: 612-624-8935

November 29, 2004

Jeffery Perkey  
IACUC  
MMC 820  
CAMPUS MAIL

RE: "Primate Model of Drug Abuse: Intervention Strategies"  
"Imaging the Effects of Drug Use and Cessation on Monkey Brain"  
Animal Subjects Code Number 0410A64755

Dear Mr. Perkey:

This letter is in response to your letter of November 12, 2004 in which you listed stipulations resulting from the November 9, 2004 review of the above-referenced protocol.

OK 1) What was accomplished during the prior approval period? The goals have been partially completed during the first 3 of the 5-year grant period. The remaining goals will be completed during the last 2 years of the grant and the first year of the competing renewal. For example:

Goal 1: We have studied sex differences in drug abuse but not hormonal effects.

Goal 2: Completed.

Goal 3: We have studied the effects of saccharin on oral PCP and ethanol self-administration, but we have not yet examined cocaine and heroin smoking.

Goal 4: We have studied bremazocine and published the results, but we have not yet had much success with baclofen. We are going to work with SR-141716A, a CB1 antagonist, and we have added that to the protocol on amended pages that are attached.

Goal 5: Completed.

2) Please clarify the number of animals requested for purchase, transfer and clarify the justification. We have always worked with a group of 34 animals, and that was what we planned for when designing the grant experiments. That number was determined by lab space. The lab was renovated two years ago, and the lab can accommodate 4 more monkeys. Four additional monkeys were purchased on the "Imaging" grant by Kamil Ugerbil, and they are added to the 34 to equal a total of 38. We will behaviorally test the 4 monkeys, and they will image them. All 38 could reside in the \_\_\_\_\_ however, 4 are kept in the \_\_\_\_\_ the time they are being imaged. That may range from a day to several months. A total of 12 animals (4 in each of 3 groups) will be imaged. On Page 10 and in the table, 34 monkeys are mentioned. The number 37 does not appear on page 10 in my copy of the usage form.

→ Wants approval for 38 total. OK

12 of those 38 will also be used for behaviorally testing at \_\_\_\_\_ described in a May 2002 addendum to the



DEC 1 2004 PM 4:27

IACUC cannot act on a 2.5 year old addendum. Each approved protocol must clearly state all procedures to be done on each animal & justify the #s requested.

3) None of the procedures mentions imaging. Some of the monkeys in this protocol are only briefly sent over to \_\_\_\_\_ or imaging on 3 or 4 occasions. The 4 \_\_\_\_\_ monkeys that reside at \_\_\_\_\_ are imaged as controls and are added to the groups for behavioral testing, but they are not part of the "Primate Model" grant/study. More details on the imaging procedures have been added in the attached pages.

4) The committee is concerned that the animals may be considered pain class B if imaging is conducted or if animals experience withdrawal symptoms. The animals do not experience any signs of withdrawal. Since symptoms are self-reported, we do not know if they have "symptoms," but they show no obvious signs of withdrawal. Most of their drug access is short term; usually they self-administer 1 or 2 hours per day. More regular - all day intake would probably be needed to produce withdrawal effects. If MRI imaging is considered pain class B, then we should change 12 of the 38 total animals to class B and the others would remain at A. However, when we received approval for imaging 2 years ago (see attached) it was for Class A. We did not think that going into a magnet was associated with any pain.

5) It is unclear if animals on this protocol develop a tolerance to or dependence on the agents administered. A study of tolerance to PCP (Carroll, Drug and Alc Dep., 9:213-224, 1982) showed that there is only a small amount of tolerance that develops, and even after 3 or 6 hrs of PCP access there are no signs of withdrawal that would indicate dependence had developed.

6) Provide specific scientific justification for placing animals on food restriction. It is not healthy to allow NHP to free feed; they become obese, have increased health problems, and a shortened life span. The amounts these animals are fed allow them to weigh approximately 10+ kg for males and 6+ kg for females. These weights are consistent with what nonexperimental animals would weigh in a primate holding facility. In fact, some of these animals do not eat all the food they are given. The scientific basis for food restriction is that when the animals are not free-fed and obese they are more active and motivated to self-administer drugs (Carroll et al 1984, Carroll and Mattox 1997, Cabeza de Vaca and Carr, 1998).

7) Clarify the end points of the study. The end point of each study is when the data required by the experimental design are collected. This may vary from weeks to months depending on how many experimental conditions are tested, such as self-administered drug dose, treatment drug dose, behavioral schedule parameters, and nondrug control. For example, it could take several months to test several doses of a treatment drug and several concentrations of the self-administered drug under several parameters of the behavioral schedule. Between different doses of treatment medications there is usually a 5-7 day washout period. The self-administered drug is offered for a short time every day. If there are subtle, unobservable, withdrawal effects, they will not be encountered if daily drug access continued between experiments. Another factor is that the animals sometimes become irritated when their drug is taken away. Thus, in many cases we keep the animals on brief daily access to PCP when we are between experiments. When a different self-administered drug is introduced, there may be a drug-free washout period of 10-14 days, or one drug may be substituted immediately for the other to maintain self-administration behavior.

are class B if we approve imaging addendum which uses anesthesia

OK

see blue sticky note next page

OK

OK

8) Use of additional agents. A change in protocol request will be submitted when new treatment agents are obtained and planned for use. We have added one treatment drug, SR-141716A to the revised protocol (attached).

#3

9) Animal work at \_\_\_\_\_ We obtained an approved addendum to this protocol when we began imaging animals used in the "Primate Models" protocol at \_\_\_\_\_ See attached correspondence.

acuc check →

10) Kacie Griffin and Joey Thorne have completed NHP orientation/training. RAR has records on their completion of the training and they have received certificates. The IACUC's records must need updating. *what about iacuc training?*

I hope these responses to your comments adequately address the committee's questions/concerns. Thank you for the review and helpful feedback on this protocol.

Sincerely,

*Marilyn Carroll*


Marilyn E. Carroll, Ph.D.  
Professor of Psychiatry and Neuroscience

Phone: (612) 626-6289  
FAX: (612) 624-8935  
E-mail: mcarroll@umn.edu

Encl.

Revised Appendix C  
Correspondence regarding imaging project

*reviewed by CG 12/16/04*



**Eric Vegoe**

**From:** mcarroll@umn.edu  
**Sent:** Friday, December 10, 2004 12:08 PM  
**To:** Eric Vegoe  
**Subject:** Re: November 29, 2004 Response - Protocol 0410A64755

Dear Eric:

The following are responses to your additional stipulations:

Dr. Carroll,

The IACUC received your November 29, 2004 and it was reviewed by an institutional veterinarian. There are some additional clarifications needed before approval can be processed.

1) Your response to point three states that some NHPs are briefly sent over to CMRR for imaging on 3 or 4 occasions. The IACUC cannot approve the attached procedures which appear to be from a previous submission. Each protocol must specifically detail what is done to animals on the current protocol. The attachment is a general procedure, and doesn't detail how the procedure is applied to this protocol. Please clearly detail what procedures will be done on which animals for this protocol, and then scientifically justify the number of animals used for each group.

*OK except that scientific justification for the numbers of animals in each group not provided*

As an addendum to the behavioral studies that are described in the protocol 12 monkeys will be scanned by an MRI at the . There will be 3 groups of 4 monkeys: 1) those experienced with smoking cocaine base while they are smoking daily and for 6 months after their access to smoking has been terminated, 2) drug naive monkeys who are being trained to smoke and just beginning to smoke, over the 6 months of acquisition, and 3) controls that never smoked cocaine. Two monkeys have been purchases by . When we have 2 monkeys from group 1 that need to be imaged for 6 months after they stop, they will be housed at , and the 2 drug-naive ones will come to the . o be trained to smoke cocaine. We have 2 of those monkeys here now , and we will soon be sending . Otherwise, when we scan any of the monkeys in these 3 groups, the are taken over there by RAR personnel at 2 pm, scanned, and returned to our lab by about 5 pm. They do not reside at

When the monkeys are to be scanned they are transferred into a portable transfer cage, and carried across campus in a heated truck by RAR personnel (Paula). Upon arrival, they are anesthetized with ketamine (15 mg/kg i.m.), intubated, and placed on a respiratory assist machine. Anesthesia is maintained by isoflurane (1% in N<sub>2</sub>O/O<sub>2</sub>). The monkeys are placed face down on a specifically-designed primate cradle that restrains their head from movement and cushions pressure points. Foam earplugs 10dB are used to minimize auditory stimulation due to noise generated by the RF sequence. Each procedure lasts about 2 hours, and at the end of the scan the monkeys are returned to a holding cage and observed until they recover from anesthesia (are able to hold their head up). They are then coaxed to jump back through an opening in the cage door to the attached transfer cage, loaded back into

the truck, driven back to the \_\_\_\_\_, and transferred back into their home cage.

Each monkey in the 3 groups will have 3 - 4 scans separated by at least a month. If there are equipment or data collection problems with the MRI devices, 2 or 3 additional scans may be necessary. This is a new procedure, and problems with data collection occasionally arise.

This scanning procedure with the 12 (or up to 18) monkeys was brought before the IACUC as an addendum to the Primate Model protocol (0112A14081), and it was approved July 17th, 2002. That's why I didn't think that part of the protocol had expired yet and needed to be renewed. But obviously it is part of the original protocol which expired. Please accept this description of the procedures as part of the currently expiring protocol that I am trying to renew.

2) Your response to the six point includes your justification for food restriction. You indicate that it is healthier, but this is not scientific justification for food restriction. It is the committee's experience that 85% weight maintenance is typically associated with inducing subject animals to perform behavioral procedures. Limited feeding may be done by the RAR husbandry staff upon veterinary approval for health reasons. Any other use of restricted feeding by a PI requires scientific justification that it is integral and necessary to the research objectives.

< We maintain monkeys at 85% of their free-feeding weight to obtain stability on our behavioral procedures. They are more likely to self-administer drugs and in a more consistent manner when they are mildly food restricted. The 85% calculations were based on several weeks of free feeding, and since the monkeys overeat and sometimes become obese when they are free-fed, the 85% weights are actually quite generous, like I said averaging over 10 kg for males and over 6 kg for females. Some do not eat all the food they are given.

? not fix  
if ca-  
xif

It is an aside really that they are healthier on this regimen. Reduced food access not only extends their life-span, but reduces the amount of food left in the cage, which can be a vector for infection and illness.

I hope this additional information is satisfactory; please let me know if you require any additional information. Thank you for your careful review and attention to details.

Marilyn Carroll

Please address these concerns in a reply to this e-mail.

Sincerely,

Eric Vegoe

IACUC - RSPP

Univ of Minnesota

#2-ok  
#1- still needs numbers justification, also needs brief statement of goals/objectives of the MRI scans -> "as an addendum to the behavioral studies" is not sufficient  
Cg 12/13/04

612-626-5654 - phone

612-626-6061 - fax

[vegoe004@umn.edu](mailto:vegoe004@umn.edu) - e-mail

--

Marilyn E. Carroll, Ph.D.  
Professor of Psychiatry and Neuroscience  
Department of Psychiatry  
Mayo Box 392  
University of Minnesota  
Minneapolis, MN 55455

email        [mcarroll@umn.edu](mailto:mcarroll@umn.edu)  
Office phone    612-626-6289  
Fax            612-624-8935

**Eric Vegoe**

---

**From:** mcarroll@umn.edu  
**Sent:** Wednesday, December 15, 2004 11:15 AM  
**To:** Eric Vegoe  
**Subject:** RE: November 29, 2004 Response - Protocol 0410A64755

An institutional veterinarian reviewed your response and requested an additional clarification.

You have clearly detailed the procedures performed on the animals and the number of animals used on each procedure, but you have not provided scientific justification for the number of animals used. Please detail the reasoning, models, literature or statistical analysis that led you to scientifically determine the specific number of animals requested. Please also detail the goals and objectives of the MRI scans.

The number of monkeys per group in the proposed experiments is 6-7. We have arrived at this number from previous statistical analysis of protocols involving similar dependent measures. This number of animals per group is necessary to have statistical power to compare across groups with analyses of variance. The goals and objectives of the MRI scans are to examine white matter in the brains of monkeys that are at various stages of the cocaine addiction process to determine whether there is short or long term changes in brain matter as a result of cocaine use.

Marilyn Carroll

You may reply by e-mail to speed the review process.

Sincerely,

Eric Vegoe

64755

OKcg  
12/16/04

--

Marilyn E. Carroll, Ph.D.  
Professor of Psychiatry and Neuroscience  
Department of Psychiatry  
Mayo Box 392  
University of Minnesota  
Minneapolis, MN 55455

12/15/2004

email mcarroll@umn.edu  
Office phone 612-626-6289  
Fax 612-624-8935



# UNIVERSITY OF MINNESOTA

---

*Research Subjects' Protection Programs  
Institutional Review Board: Human Subjects Committee (IRB)  
Institutional Animal Care and Use Committee (IACUC)*

*Mayo Mail Code 820  
D-528 Mayo Memorial Building  
420 Delaware Street S.E.  
Minneapolis, MN 55455*

December 17, 2004

Marilyn E. Carroll  
Psychiatry  
MMC 392 Mayo  
420 Delaware  
Minneapolis MN 55455

*612-626-5654  
Fax: 612-626-6061  
irb@umn.edu  
iacuc@umn.edu  
www.irb.umn.edu  
www.iacuc.umn.edu*

Re: "Imaging the Effects of Drug Use and Cessation on Monkey Brain"  
"Primate Model of Drug Abuse: Intervention Strategies"  
Animal Subjects Code Number: **0410A64755**

Dear Dr. Carroll:

The Institutional Animal Care and Use Committee (IACUC) received your response to its stipulations. Since this information satisfies the requirements set by the IACUC, final approval for the project is noted in our files. The study is approved for the purchase of 12 Class B NHPs and the purchase of 26 Class A NHPs. The code number above and the title of your study should be used in all communication with the IACUC office.

Please note that it is your responsibility to notify your funding agency of any changes to your proposed animal care and use that have occurred as a result of IACUC review and approval.


For your records and for grant certification purposes, the approval date for the referenced project is December 16, 2004. A request for continuing approval will be sent two months prior to its expiration date. In addition, new applications will be required for ongoing IACUC protocols every three years.

The date of our last AAALAC accreditation is March 2004, and the Assurance of Compliance number is A3456.

As Principal Investigator of this project, you are required by federal regulations to inform the IACUC of any proposed changes in your research involving the use of animals. Changes should not be initiated until written IACUC approval is received. Please keep copies of this application available for reference by individuals involved in conducting this research project.

If you would like certification of approval sent to your funding agency, please provide the name and address of your contact person at that agency.

Sincerely,



Jeffery Perkey, CIP  
Executive Assistant, IACUC

JP/ejv



NHP QUARANTINE


DATE 11/26/97  
INVESTIGATOR/DEPT. Carroll/monkeys 9602A00037 4456151  
DOA/ VENDOR/ RAP Michigan Biol 6411  
SPECIES M. mulatta  
SEX fe  
ID/TATTOO 9711 B

DATE 11/26/97  
WEIGHT 4.65Kg  
TB TEST (R) neg  
HEALTH HISTORY: appears to have no eyelids - PI notified  
Vet. V'd. PI concerned because animal will be long term  
will have ophthalmology consult fecal Blood drawn  
Injections: 2

DATE 12/18/97  
WEIGHT 4.9  
TB TEST (L) neg  
HEALTH HISTORY:  
teeth cleaned appears in good health  
nail trim  
10 tattoo/chest Injections 8q SF

DATE  
WEIGHT  
TB TEST  
HEALTH HISTORY:  
*Wanted per Cg.*

RELEASE FROM QUARANTINE: 12/21<sup>SF</sup>/97 SF



DATE 11/26/97  
 LAB NO. \_\_\_\_\_  
 INVESTIGATOR Carroll/monkeys  
 DEPARTMENT Psych. Res.  
 CLINICIAN WU  
 LAB TECH \_\_\_\_\_  
 PROTOCOL # \_\_\_\_\_  
 OR CUPS 9602A0037

SPECIES MAM  
 BREED/STRAIN \_\_\_\_\_  
 ANIMAL ID# 9711B  
 AGE 3yrs. SEX fe  
 CLINICAL CASE quarantine  
 NECROPSY CASE \_\_\_\_\_  
 NECROPSY # \_\_\_\_\_  
 ROOM # \_\_\_\_\_  
 SERUM CHEMISTRIES \_\_\_\_\_

PROV Dx \_\_\_\_\_  
 Dx A. \_\_\_\_\_  
 Dx B. \_\_\_\_\_  
 Dx C. \_\_\_\_\_  
 RAR RESEARCH \_\_\_\_\_  
 TITLE \_\_\_\_\_

**HEMATOLOGY**

10.6 10-3 WBC  
5.54 10-6 RBC  
12.6 G/DL HGB  
38.9 % HCT  
70 UM3 MCV  
22.7 UUG MCH  
32.4 G/DL MCHC  
452 10-3 PLT  
7.0 G/DL TPP

**DIFFERENTIAL**

% DIFF CLS x 10-3  
48 SEGS 5.04  
0 BANDS 0.00  
46 LYMPH 4.93  
6 MONO 0.64  
0 EOS 0.00  
0 BASO 0.00

BUN (mg/dl) \_\_\_\_\_  
 CREAT (mg/dl) \_\_\_\_\_  
 GLUCOSE (mg/dl) \_\_\_\_\_  
 TOTAL BILIRUBIN \_\_\_\_\_  
 AMYLASE \_\_\_\_\_  
 COMMERCIAL CHEM. \_\_\_\_\_  
 OTHER \_\_\_\_\_

**SEROLOGY**

ELISA-M. PULMONIS \_\_\_\_\_  
 SENDAI \_\_\_\_\_  
 RCV \_\_\_\_\_  
 MHV \_\_\_\_\_  
 OTHER \_\_\_\_\_  
 PVM \_\_\_\_\_  
 GD VII \_\_\_\_\_

**BLOOD PARASITES**

HEARTWORM TEST \_\_\_\_\_  
 INTRACELLULAR PARASITE Neg

**FECAL EXAMINATION**

ENDOPARASITES  
 A. feces Neg  
 B. \_\_\_\_\_  
 C. \_\_\_\_\_

**OCCULT BLOOD**

**URINALYSIS**

COLOR \_\_\_\_\_  
 CLARITY \_\_\_\_\_  
 SP. GRAVITY \_\_\_\_\_  
 pH \_\_\_\_\_  
 PROTEIN \_\_\_\_\_  
 GLUCOSE \_\_\_\_\_  
 KETONE \_\_\_\_\_  
 RBC \_\_\_\_\_  
 BILIRUBIN \_\_\_\_\_  
 MICRO \_\_\_\_\_

**MICROBIOLOGY**

SOURCE (SPECIMEN)  
 A. feces  
 B. \_\_\_\_\_  
 C. \_\_\_\_\_  
 D. \_\_\_\_\_  
 ROUTINE \_\_\_\_\_  
 ANAEROBE \_\_\_\_\_  
 MYCOPLASMA \_\_\_\_\_  
 FUNGUS \_\_\_\_\_  
 SALMONELLA \_\_\_\_\_  
 OTHER Shigella

**SKIN SCRAPINGS**

ECTOPARASITES \_\_\_\_\_  
 KOH PREP \_\_\_\_\_

**STAIN**

GRAM \_\_\_\_\_  
 GIEMSA \_\_\_\_\_  
 OTHER \_\_\_\_\_  
 STAIN INTERPRETATION \_\_\_\_\_

**SENSITIVITY**

ORGANISM \_\_\_\_\_  
 AMIKACIN \_\_\_\_\_  
 AMOXI/CLAV. ACID \_\_\_\_\_  
 AMPICILLIN \_\_\_\_\_  
 CEPHALOTHIN \_\_\_\_\_  
 CEFTIOFUR \_\_\_\_\_  
 CHLORAMPHENICOL \_\_\_\_\_  
 CIPROFLOXACIN \_\_\_\_\_  
 CLINDAMYCIN \_\_\_\_\_  
 ERYTHROMYCIN \_\_\_\_\_  
 GENTAMYCIN \_\_\_\_\_  
 PENICILLIN \_\_\_\_\_  
 SMZ-TMP \_\_\_\_\_  
 TETRACYCLINE \_\_\_\_\_  
 TICARCILLIN \_\_\_\_\_

**RESULTS**

A-1 No pathogens isolated.  
 2 \_\_\_\_\_  
 3 \_\_\_\_\_  
 4 \_\_\_\_\_  
 5 \_\_\_\_\_  
 B-1 \_\_\_\_\_  
 2 \_\_\_\_\_  
 3 \_\_\_\_\_  
 C-1 \_\_\_\_\_  
 2 \_\_\_\_\_  
 D-1 \_\_\_\_\_

COPIES TO :

University of Minnesota  
Veterinary Teaching Hospitals  
CLINICAL CHEMISTRY

Date 11/26/97

CASE NO. 32170

OWNER 1160-625-2040 Gebhart RAR

Time 10:38

LAB #	CLINICIAN	STUDENT	SPECIES
7482	Research / D-Lab		Primate
HEMOLYSIS			BREED
LIPEMIA			AGE/DOB 09/30/98
<input type="checkbox"/> CLARIFIED	RAR/Gebhart/Rhesus 9711B		SEX
ICTERUS			NAME/TAG #
<input type="checkbox"/> RESULTS			IP
QUESTIONABLE	<input type="checkbox"/> Process only		Charge to:
DUE TO	<input type="checkbox"/> Short term save(2 mo) _____ ml frozen		<input type="checkbox"/> CLIENT
CONDITION OF	<input type="checkbox"/> Long term save(2 yrs) _____ ml frozen		<input type="checkbox"/> TEACHING
SAMPLE	N.B.: Sera remaining from completed tests are held one week at N/C		<input type="checkbox"/> GRANT
			TOTAL 23.62

K9 Profile

CX7 Lab number:  
Date: 11/26/97 Time: 12:36  
Type: Routine Serum

ALB	5.3	g/dL
ALP	477	U/L
ALT	22	U/L
AMY	330	U/L
AST	37	U/L
BILI.T.	0.1	mg/dL
BUN	15	mg/dL
CHOL	187	mg/dL
CO2	27.2	mmol/L
Calcium	9.9	mg/dL
Chloride	110	mmol/L
Creatinine	0.7	mg/dL
Glucose	62	mg/dL
MG	1.6	mg/dL
PHOS	4.4	mg/dL
Potassium	3.6	mmol/L
Sodium	143	mmol/L
TP	6.5	g/dL

\*\*\*\*\* Calculated Value \*\*\*\*\*

21	BUN/CREA RATIO
284	OSMOLALITY (1)
6	ANION GAP

Technologist 11/26/97 13:12 lm

Clinician

**UNIVERSITY OF MINNESOTA**  
**DEPARTMENTAL PURCHASE ORDER - POT**

Order Nbr. 845 20000008  
 Area  
 All 11 Digits Must Be Referenced On Invoice

This order **MUST NOT** exceed \$2,000 unless a valid University Contract number is referenced, or order is centrally issued. If \$500 or over and using sponsored funds, this order **MUST BE** approved by ORTTA.

**Reasonable price:** University departments are accountable for ensuring that they pay reasonable prices for all their purchases. Reasonable prices are assured by buying from University-wide contract vendors; or by comparing quotes from several sources; or by comparing to prices paid for similar purchases; or by department's knowledge of the market; or by any other means that provides assurance of a reasonable price.

If Checked, this is a Confirming Order  
 Do Not Duplicate  
 Contract Number (if applicable)  
 84520000008 TNS

Order Date (MMDDYY) 10/27/97

Vendor Number 0000234639  
 MICHIGAN BIOLOGICAL PRODUCTS  
 3500 N MARTIN LUTHER KING  
 LANSING MI 48909

(P) 517/335-8145 **BILL IN DUPLICATE** (F) 517/335-9486

Bill To: UNIVERISTY OF MINNESOTA  
 612-625-6169  
 MINNEAPOLIS MN 554550392  
 Ship To: UNIVERSITY OF MINNESOTA  
 612-624-6169  
 MINNEAPOLIS MN 554550354

Payment Terms NET 30 DAYS Estimate  Yes No  
 Delivery Date (MMDDYY) by arrangement FOB (see Terms & Conditions)

ILOC Code \_\_\_\_\_  
 Internal Destination  
 RES ANIMAL RE 612-624-6169  
 MINNEAPOLIS MN 554550392

3 Area	4 Org	2 Sub Org	4 Obj	2 Sub Obj	5 Job Number	8 Reporting Category	14 Total Amount
845	2030		7320	10			4,900.00

OR  Split Account Distribution See Attached

**DO NOT USE THIS FORM TO PURCHASE RESTRICTED COMMODITIES**

Qty	Unit Meas	Description	Unit Price	Extension
2.00	EACH	HEALTHY FEMALE RHESUS MONKEYS, ID# P1 & P7. MUST BE HERPES B NEGATIVE, TB NEGATIVE, HEALTHY, HEALTHY GUAGANTEED.	2200.000	4,400.00
2.00	EACH	SHIPPING CRATES (ESTIMATES)	75.000	150.00
1.00	LOT	ESTIMATED AIR SHIPPING	350.000	350.00
PER RX 84561050812				

**VENDOR COPY FAXED**

APPROVED  
  
 For Director of Purchasing Services

Department Name RESEARCH ANIMAL RESOURCES Date  
 Requested By Phone

TERMS AND CONDITIONS ATTACHED

4602A00031

6456151

Health Sciences  
University of Minnesota

Species M. mulatta Tattoo # 9711B PI Estimated Age \_\_\_\_\_  
Sex female Date Received 11/22/97 Vendor Michigan Bio Products  
Investigator Carroll/monkey  
Department Psych Res Room No. \_\_\_\_\_

Quarantine: TB Tests

1st: Date 11/26/97 2nd: Date 12/18/97 3rd: Date \_\_\_\_\_  
Results neg Results neg Results \_\_\_\_\_  
Wt. kg. 4.125 Wt. kg. 4.9 Wt. kg. 4.9

CBC \_\_\_\_\_  
WBC ( $10^3/\text{mm}^3$ ) \_\_\_\_\_  
ZSEGS \_\_\_\_\_  
BANDS \_\_\_\_\_  
LYMPHOCYTES \_\_\_\_\_  
MONOCYTES \_\_\_\_\_  
EOSINOPHILS \_\_\_\_\_  
BASOPHILS \_\_\_\_\_  
NRBC/100WBC \_\_\_\_\_  
OTHER \_\_\_\_\_

RBC ( $10^6/\text{mm}^3$ ) \_\_\_\_\_  
MCV \_\_\_\_\_  
MCHC \_\_\_\_\_  
HCT (%) \_\_\_\_\_  
Hb (G/DL) \_\_\_\_\_  
M-TOTAL PROTEIN \_\_\_\_\_  
PLATELETS \_\_\_\_\_  
BLOOD MORPHOLOGY \_\_\_\_\_

FECAL EXAMINATION  
ENDOPARASITES  
A \_\_\_\_\_  
B \_\_\_\_\_  
C \_\_\_\_\_  
D \_\_\_\_\_  
WORMING \_\_\_\_\_

BLOOD SMEAR  
(PROTOZOA) \_\_\_\_\_

Comments \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date of last negative Tuberculin skin tests and weights/kg:

12-18-97	4.9								
4-14-98	5.0								

Clinical History: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_



Suzanne

Reqnumber  
006411

Tech	Chris
Sup	CJM
# Cards	

# Request for Animal Purchase

Area 645    Org 6151    Suborg    Protocol Number: 9602A00037

Investigator: **Carroll/Monkeys**

Department: **Psychiatry**

Contact Person: **Dr.Carroll 426-4603**

Phone: **6-6289**

Housing in Research Animal Resources Operated Facility?	<b>Yes</b>
Building and/or room preferred:	
Approximate length of housing:	
Building or room to be delivered to:	
Where do you plan to pick up the animals?	<i>~4pm</i>

Vendor: **Michigan Biological Produ**

Date Required: **11/12/97**

Number: **2**

Species: **Non-Human**

Strain: **rhesus**

Sex: **Female**

Other Special Requirements/Comments:  
**~4kg. Contact: Barbara Kinter**

Age/Weight: **3 years**

USDA Information: Pain Usage Level: **A**

**RAR USE ONLY**

Order Received: **11/07/97 09:06:14**  
Order Revised:

Received By: \_\_\_\_\_  
Revised By: \_\_\_\_\_

### Ordering Information:

Units:	_____	Vendor Contact: <b>Barb</b>
Unitcost	_____	_____
Boxcharge	_____	Ordered By/Date: <b>MS      11/07/97</b>
Shipping	_____	Vendor Invoice #: _____
Othercosts	_____	_____
		U of M Invoice #: _____
		U of M PO #: _____
	Total	_____

**9711A,B**



MICHIGAN BIOLOGIC PRODUCTS INSTITUTE  
MANUFACTURING DIVISION  
BIO SALES

234639-0

INVOICE

Enacted Under Authority of ACT 368 P.A. 1978

Failure to conform payment by the date due will result in a penalty as prescribed by law

BILL TO:

UNIVERSITY OF MINNESOTA  
RESEARCH ANIMAL RESOURCES

INVOICE NUMBER: 735

Invoice Date: January 21 1998

SHIPPED TO  
UNIVERSITY OF MINNESOTA

JAN 27 1998

MINNEAPOLIS MN 55455

MINNEAPOLIS MN 55455

ANY QUESTIONS: PLEASE CALL (517) 335 8058  
po #8450000063

Invoice Item	Ship Date	Quantity	Unit Cost	Total Cost
RHESUS MONKEY - P11 - MALE	1/15/98	1	\$2,200.00	\$2,200.00
RHESUS MONKEY - P7 - FEMALE		1	\$1,950.00	\$1,950.00
CRATE/SHIPPING		2	\$75.00	\$150.00

NOT a V-T  
234639-0  
BY 10/27

U.S. MAIL PERMIT NO. 1208A (Rev. 7/91)

Postage and Fees Paid

735

UNIVERSITY OF MINNESOTA

RESEARCH ANIMAL RESOURCES

MINNEAPOLIS MN 55455

1 2774 4 (16)

53000932

EXP. DATE

ISSUE DATE

Total Amount \$4,300.00

Shipping/Handling \$342.94

Sales Tax \$0.00

Total Invoice \$4,642.94

Payment Due 02/20/98

INVOICE NO: 735  
MFG. SALE

MAKE CHECK OR MONEY ORDER PAYABLE TO STATE OF MICHIGAN  
TO ENSURE PROPER CREDIT SEND THIS PORTION WITH PAYMENT TO  
MICHIGAN DEPARTMENT OF COMMUNITY HEALTH  
ACCOUNTING - BIO  
P O BOX 30437  
LANSING MI 48909

UNIVERSITY OF MINNESOTA  
RESEARCH ANIMAL RESOURCES  
MINNEAPOLIS MN 55455  
OML-30 (Rev. 11/91)

For Cashier's Use Only:

53000932

Total Due \$4,642.94



# Animal Morbidity Report

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 12/10/1997 Time 11:46:54 AM Initials DMC Attitude Responsiveness Posture  
Recovery- IV Minimal Recumbant  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
Normal

MM Color CRT (s) Hydration Systems Exam (Check if Abnormal)  
Normal

Pink Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

Palpebral defect noted and reported by veterinary staff.  
 3 mm wide by 1 mm deep defect of superior palpebra OS. Slight pigmentation and alteration of hair pattern in area. No evidence of corneal scarring, edema, pigmentation or conjunctivitis.  
 The defect appears to be the result of an old injury. Congenital cause cannot be ruled out. Because of the probable duration of defect with no apparent ocular lesions it is to be considered benign little chance of long-term complications. This assessment correlated by a human ophthalmologist consultant.

Plan  
 Monitor only for development of ocular lesions. If investigator this animal is assigned to does not want the animal, it may be reassigned with precautions about using a parasympatholytic drug such as atropine that may promote keratitis sicca.

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 3/25/1998 Time 12:28:28 PM Initials Attitude Responsiveness Posture  
Recovery- IV Minimal Recumbant  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character

MM Color CRT (s) Hydration Systems Exam (Check if Abnormal)  
Normal

Pink Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

Released from quarantine on 12-97.  
 Will be TB tested every 6 months, last negative test on 12-18-97.

Plan

Research Animal Resources, University of Minnesota  
**Animal Morbidity Report**

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 12/10/1997 Time 11:46:54 AM initials DMC Attitude Recovery- IV Responsiveness Minimal Posture Recumbant  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character Normal  
 MM Color CRT (s) Hydration Normal Systems Exam (Check if Abnormal)  
 Pink Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./ Location  
 Incision Condition

**Progress Notes**

Palpebral defect noted and reported by veterinary staff. 3 mm wide by 1 mm deep defect of superior palpebra OS. Slight pigmentation and alteration of hair pattern in area. No evidence of corneal scarring, edema, pigmentation or conjunctivitis. The defect appears to be the result of an old injury. Congenital cause cannot be ruled out. Because of the probable duration of defect with no apparent ocular lesions it is to be considered benign little chance of long-term complications. This assessment correlated by a human ophthalmologist consultant.

Plan Monitor only for development of ocular lesions. If investigator this animal is assigned to does not want the animal, it may be reassigned with precautions about using a parasympatholytic drug such as atropine that may promote keratitis sicca.

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 3/25/1998 Time 12:28:28 PM initials  Attitude  Responsiveness  Posture   
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character   
 MM Color CRT (s) Hydration  Systems Exam (Check if Abnormal)  
 Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./ Location  
 Incision Condition

**Progress Notes**

Released from quarantine on 12-97. Will be TB tested every 6 months, last negative test on 12-18-97.

Plan

# Animal Morbidity Report

**Signalment:** **Master Problem List** Medical Record # 97MR-661 Protocol No. 9602037

ID 9711B Billing Name Carroll  
 Species Rhesus Strain  
 Sex F Age Age DOB 11/19/97 DOA  
 Weight 4.65 kg Vendor

Problem	No. Animals	Date Active	Resolved	Final Disposition	Date	Necropsy No.
Palpebral defect	1	12/10/97				

## Master Treatment List:

Investigator	Lab Number	Treatment	Dose	Rt.	Frequ.	Started	Compl.	Preventative Medicine	Date
Carroll		Monitor for ocular lesions		OS	Daily	12/10/97			
Department									
Psychiatry									
Contact									
Sherrie									
Phone									
6-6301									

**Daily Observations:** Building KE Room:Run 43  Post-Op  General

**Experimental History**

None in quarantine

**Medical History**

Palpebral defect noted and reported by veterinary staff

**Special Requests**

Date 12/10/97 Time 11:46:54 Initials DMC Attitude Recovery- I√ Responsiveness Minimal Posture Recumbant  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character Normal

MM Color CRT (s) Hydration Normal Systems Exam (Check if Abnormal)

Incision/Lesion Location Incision Condition  Altitude  Respiratory  Gastrointestinal  Neurologic  Optic/Otic  
 Integument  Cardiovascular  Musculoskeletal  Urogenital

Treatments Given:

**Other Observations**

3 mm wide by 1 mm deep defect of superior palpebra OS. Slight pigmentation and alteration of hair pattern in area. No evidence of corneal scarring, edema, pigmentation or conjunctivitis

**Assessment**

The defect appears to be the result of an old injury. Congenital cause cannot be ruled out. Because of the probable duration of defect with no apparent ocular lesion is to be considered benign little chance of long-term complications. This assessment correlated by a human ophthalmologist consultant

**Plan**

Monitor only for development of ocular lesions. If investigator this animal is assigned to does not want the animal, it may be reassigned with precautions about use a parasympatholytic drug such as atropine that may promote keratitis sicca

# Animal Morbidity Report

Daily Observations: ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 7/1/1998 Time 4:57:13 PM Initials \_\_\_\_\_ Attitude \_\_\_\_\_ Responsiveness \_\_\_\_\_ Posture \_\_\_\_\_  
 Appetite \_\_\_\_\_ Water Consumption \_\_\_\_\_ Stool \_\_\_\_\_ Urine \_\_\_\_\_  
 Temp. \_\_\_\_\_ Pulse \_\_\_\_\_ Resp. \_\_\_\_\_ Pulse Character \_\_\_\_\_ Resp. Character \_\_\_\_\_  
 MM Color \_\_\_\_\_ CRT (s) \_\_\_\_\_ Hydration \_\_\_\_\_

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

Negative TB test on 4-14-98

Plan

Daily Observations: ID 9711B

Building

Room

- Post-Op
- Part. PO
- General

Special Requests

Date 10/15/19 Time 2:09:23 Initials SF Attitude \_\_\_\_\_ Responsiveness \_\_\_\_\_ Posture \_\_\_\_\_  
 Appetite \_\_\_\_\_ Water Consumption \_\_\_\_\_ Stool \_\_\_\_\_ Urine \_\_\_\_\_  
 Temp. \_\_\_\_\_ Pulse \_\_\_\_\_ Resp. \_\_\_\_\_ Pulse Character \_\_\_\_\_ Resp. Character \_\_\_\_\_  
 MM Color \_\_\_\_\_ CRT (s) \_\_\_\_\_ Hydration \_\_\_\_\_

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

weight 5.0kg

Plan

# Animal Morbidity Report

Daily Observations:

ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 12/10/1998 Time 3:54:07 PM Initials

Attitude

Responsiveness

Posture

Appetite

Water Consumption

Stool

Urine

Temp.

Pulse

Resp.

Pulse Character

Resp. Character

MM Color

CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./

Location

Incision

Condition

Progress Notes

sedated for eye exam

Plan

Daily Observations:

ID 9711b

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 2/9/1999 Time 4:28:54 PM Initials SF

Attitude

Responsiveness

Posture

Appetite

Water Consumption

Stool

Urine

Temp.

Pulse

Resp.

Pulse Character

Resp. Character

MM Color

CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

observation

Incision No./

Location

Incision

Condition

Progress Notes

animal received a minor scrape lateral to the left eye... and a minor laceration across the nose during an escape from it's cage. LACT netted monkey and returned her to cage

Plan

no treatment at this time just observe for resolution. Cage was secured to prevent future escape



# Animal Morbidity Report

**Daily Observations:**

ID 9711b

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 2/10/1999 Time 5:07:52 PM Initials

Attitude

Responsiveness

Posture

Appetite

Water Consumption

Stool

Urine

Temp.

Pulse

Resp.

Pulse Character

Resp. Character

MM Color

CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./

Location

Incision

Condition

Progress Notes

scrape is resolving and requires no treatment, monkey has good appetite and is BAR

Plan

monitor on daily rounds

**Daily Observations:**

ID 9711b

Building

Room: Run

- Post-Op
- Part. PO
- General

Special Requests

Date 3/3/1999 Time 11:31:39 Initials SW

Attitude

Responsiveness

Posture

Appetite

Water Consumption

Stool

Urine

Temp.

Pulse

Resp.

Pulse Character

Resp. Character

MM Color

CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./

Location

Incision

Condition

Progress Notes

Case discharged by veterinarian

Plan

# PHYSICAL EXAMINATION

ID N	774B	DATE	3-23-99	AGE	F	SEX	F	Wt (kg)	4.8
<input checked="" type="checkbox"/> ROUTINE <input type="checkbox"/> CLINICAL <input type="checkbox"/> PRE-SALE <input type="checkbox"/> QUARANTINE <input type="checkbox"/> OTHER									
ANESTHETIC AGENT				→		AMOUNT		TIME	
						AMOUNT		TIME	
SUPPLEMENTAL DRUGS				→		AMOUNT		TIME	
TEMP		102.4		HEART RATE		RESP		PULSE	

## PARAMETERS EXAMINED

SYSTEM	ABN	NOR	NOT OBS	SYSTEM	ABN	NOR	NOT OBS
1. INTEGUMENT	✓			6. NERVOUS			C
2. RESPIRATION		✓		7. MUSCULOSKELETAL		C	
3. CARDIOVASCULAR		✓		8. LYMPHATIC		C	
4. GASTROINTESTINAL	✓			9. ENDOCRINE			C
5. UROGENITAL		✓		10. SPECIAL SENSES			C

**COMMENTS**

(A) Diffuse moderate alopecia on extremities and ventrum of torso. Skin and conjunctiva appear to be dermated / scurred w/ slight hypertrophy of conj.  
 (B) Dental furia (malocclusion)

TBR) EYE

**DIFFERENTIAL DIAGNOSIS(ES)**

**SUBMITTING (Only those items checked were submitted; others are "NA")**

- |  |   |   |   |
|--|---|---|---|
| <input type="checkbox"/> CBC/BUN       | <input type="checkbox"/> BLOOD CULTURE      | <input type="checkbox"/> SMAC                 | <input type="checkbox"/> VIRAL TESTING    |
| <input type="checkbox"/> FECAL CULTURE | <input type="checkbox"/> FECAL PARASITOLOGY | <input type="checkbox"/> OCCULT BLOOD (FECES) | <input type="checkbox"/> MACAQUES         |
| <input type="checkbox"/> URINALYSIS    | <input type="checkbox"/> RADIOGRAPHS        |   | <input type="checkbox"/> PAN TROGLODYTES  |
| <input type="checkbox"/> OTHER (list)  |   |   | <input type="checkbox"/> SRV              |
|  |   |   | <input type="checkbox"/> SIV              |
|  |   |   | <input type="checkbox"/> HERPES-VIRAL ISO |
|  |   |   | <input type="checkbox"/> HERPES-AB        |
|  |   |   | <input type="checkbox"/> Other            |

**TREATMENT**

**SIGNATURE**

*Scott Walden DVM*

**DATE**

3-23-99

# Animal Morbidity Report

Daily Observations: ID 9711b Building Room:  Post-Op

Special Requests  Part. PO

Date 3/23/1999 Time 5:20:05 PM Initials SF Attitude Responsiveness Posture  General

Appetite Water Consumption Stool Urine

MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

Temp=102.4...wt=4.8kg...PE...TB test...denail cleaning...and nail trim done...Diffuse/moseerate alopecia on extremities and ventral torso...Skin and conjunctiva appear to be deformed/scarred with slight hypertrophy of the conjunctiva...Dental tartar/calculi noted

Plan

Daily Observations: ID 9711b Building Room:  Post-Op

Special Requests  Part. PO

Date 4/28/199 Time 4:00:02 Initials SW Attitude Responsiveness Posture  General

Appetite Water Consumption Stool Urine

MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

Case discharged by veterinarian

Plan

# Animal Morbidity Report

**Daily Observations:** ID 9711B Building Room:  Post-Op  Part. PO  General

Special Requests

Date 8/9/1999 Time 4:51:18 PM Initials SW Attitude Responsiveness Posture  
Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

Case discharged by veterinarian.....

Plan

**Daily Observations:** ID 9711B Building Room:  Post-Op  Part. PO  General

Special Requests

Date 9/7/2000 Time 2:40:00 PM Initials DF Attitude Responsiveness Posture  
Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight 7.2kg

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

Ketamine 0.6mls. HR..180...Temp..103.4.....  
TB test L eyelid. (eyelid very small).....  
1ml PenG IM L thigh.....  
TNT dental.....

Plan

ID NO: 971B      DATE: 3/7/00      AGE: Adoles.      SEX: F      WT (kg): 4.2 Kg

ROUTINE       CLINICAL       PRE-SALE       QUARANTINE       OTHER

ANESTHETIC AGENT      *Ketamine*      AMOUNT: 0.75mls      TIME:      AMOUNT:      TIME:

SUPPLEMENTAL DRUGS      →      AMOUNT:      TIME:

TEMP: 102.3      HEART RATE:      RESP:      PULSE:

**PARAMETERS EXAMINED**

SYSTEM	ABN	NOR	NOT OBS	SYSTEM	ABN	NOR	NOT OBS
1. INTEGUMENT				6. NERVOUS			
2. RESPIRATION				7. MUSCULOSKELETAL			
3. CARDIOVASCULAR				8. LYMPHATIC			
4. GASTROINTESTINAL				9. ENDOCRINE			
5. UROGENITAL				10. SPECIAL SENSES			

COMMENTS

---



---



---



---



---



---



---

DIFFERENTIAL DIAGNOSIS(ES)

---



---



---

SUBMITTING (Only those items checked were submitted; others are "NA")

CBC/BUN       BLOOD CULTURE       SMAC       VIRAL TESTING  
 FECAL CULTURE       FECAL PARASITOLOGY       OCCULT BLOOD       MACAQUES       PAN TROGLODYTES  
 URINALYSIS       RADIOGRAPHS      (FECES)       SRV       HBCAg  
 OTHER (list)       SIV       HBSAg  
 HERPES-VIRAL ISO       Anti HBS  
 HERPES-AB       Anti-HCV  
 Other       Other

TREATMENT

---



---



---

SIGNATURE      DATE

NO. 971B  
 DATE 9-7-07  
 SEX F  
 WEIGHT 7.2 kg  
 ROUTINE     CLINICAL     PRE-SALE     QUARANTINE     OTHER

ANESTHETIC AGENT	Ketamine →	AMOUNT 0.10 ml/s	TIME
		AMOUNT	TIME
SUPPLEMENTAL DRUGS	→	AMOUNT	TIME
TEMP 103.4	HEART RATE 180	RESP	PULSE

**PARAMETERS EXAMINED:**

SYSTEM	ABN	NOR	NOT OBS	SYSTEM	ABN	NOR	NOT OBS
1. INTEGUMENT				6. NERVOUS			
2. RESPIRATION				7. MUSCULOSKELETAL			
3. CARDIOVASCULAR				8. LYMPHATIC			
4. GASTROINTESTINAL				9. ENDOCRINE			
5. UROGENITAL				10. SPECIAL SENSES			

**COMMENTS**

TB test (L) eyelid  
 (not much tissue to (L) eyelid  
 1ml Penicillin 1m (L) thigh

**DIFFERENTIAL DIAGNOSIS(ES)**

**SUBMITTING (Only those items checked were submitted; others are "NA")**

- CBC/BUN     BLOOD CULTURE     SMAC     VIRAL TESTING
- FECAL CULTURE     FECAL PARASITOLOGY     OCCULT BLOOD     MACAQUES     PAN TROGLOOYTES
- URINALYSIS     RADIOGRAPHS    (FECES)
- OTHER (ISO)
- SRV     HBcAg
- SVV     HBsAg
- HERPES-VIRAL ISO     Anti-HBs
- HERPES-AB     Anti-HCV
- Other     Other

**TREATMENT**

SIGNATURE

DATE

NO. 711

DATE 9-29-73

WVC *Atal*

WV (KG) *F*

WT (KG) *5.2/Kg*

ROUTINE

CLINICAL

PRE-SALE

QUARANTINE

OTHER *✓*

ANESTHETIC AGENT →

AMOUNT

TIME

AMOUNT

TIME

SUPPLEMENTAL DRUGS →

AMOUNT

TIME

TEMP *102.3*

HEART RATE

RESP

PULSE

PARAMETERS EXAMINED

SYSTEM	ABN	NOR	NOT OBS	SYSTEM	ABN	NOR	NOT OBS
1. INTEGUMENT				6. NERVOUS			
2. RESPIRATION				7. MUSCULOSKELETAL			
3. CARDIOVASCULAR				8. LYMPHATIC			
4. GASTROINTESTINAL				9. ENDOCRINE			
5. UROGENITAL				10. SPECIAL SENSES			

COMMENTS

DIFFERENTIAL DIAGNOSIS(ES)


SUBMITTING (Only those items checked were submitted; others are "NA")

- CBC/UN
- BLOOD CULTURE
- SMAC
- VIRAL TESTING
- FECAL CULTURE
- FECAL PARASITOLOGY
- OCCULT BLOOD (FECES)
- MACAQUES
- PAN TROGLODYTES
- URINALYSIS
- RADIOGRAPHS
- SRV
- HBcAg
- OTHER (ISO)
- SIV
- HBsAg
- HERPES-VIRAL ISO
- Anti HBs
- HERPES-AB
- Anti-HCV
- Other
- Other

TREATMENT

SIGNATURE

DATE





PT \_\_\_\_\_ Dept. \_\_\_\_\_

ID NO. 971115	DATE 4-3-01	AGE 27	SEX F	WT (kg) 7.6
---------------	-------------	--------	-------	-------------

ROUTINE   
 CLINICAL   
 PRE-SALE   
 QUARANTINE   
 OTHER

ANESTHETIC AGENT TELAZOL [100mg/ml]	AMOUNT 0.23 ml	TIME
	AMOUNT	TIME

SUPPLEMENTAL DRUGS →	AMOUNT	TIME
----------------------	--------	------

TEMP 102.7	HEART RATE 174	RESP	PULSE
------------	----------------	------	-------

PARAMETERS EXAMINED:

SYSTEM	ABN	NOR	NOT OBS	SYSTEM	ABN	NOR	NOT OBS
1. INTEGUMENT				6. NERVOUS			
2. RESPIRATION				7. MUSCULOSKELETAL			
3. CARDIOVASCULAR				8. LYMPHATIC			
4. GASTROINTESTINAL				9. ENDOCRINE			
5. UROGENITAL				10. SPECIAL SENSES			

COMMENTS

---



---



---



---



---



---



---



---

DIFFERENTIAL DIAGNOSIS(ES)

---



---



---



---

SUBMITTING (Only those items checked were submitted; others are "NA")

<input type="checkbox"/> CBC/UN	<input type="checkbox"/> BLOOD CULTURE	<input type="checkbox"/> SMAC	<input type="checkbox"/> VIRAL TESTING
<input type="checkbox"/> FECAL CULTURE	<input type="checkbox"/> FECAL PARASITOLOGY	<input type="checkbox"/> OCCULT BLOOD (FECES)	<input type="checkbox"/> MACAGUES
<input type="checkbox"/> URINALYSIS	<input type="checkbox"/> RADIOGRAPHS		<input type="checkbox"/> PAN TROGLOOYTES
<input type="checkbox"/> OTHER (IIS)			<input type="checkbox"/> HBCag
			<input type="checkbox"/> HBSag
			<input type="checkbox"/> Anti Hbs
			<input type="checkbox"/> Anti HCV
			<input type="checkbox"/> Other

TREATMENT

---



---



---

SIGNATURE \_\_\_\_\_ DATE \_\_\_\_\_

# Animal Morbidity Report

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 4/30/2001 Time 3:54:55 PM Initials DF Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine  
 MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight 7.6kg

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

IB test - negative  
temp. 102.7, HR. 174

Plan

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 9/12/200 Time 8:41:52 Initials NR Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine  
 MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

Case discharged by veterinarian

Plan

PHYSICAL EXAM FORM

Date: 9/17/01 PI: M. Carroll Billing Name: Carroll Protocol: 9812A00041

Animal Information

Species: Rhesus ID#: 9711B Name: Tattoo: 9711B Sex: F

6 mo TB test  
Nail Trim  
Clinical  
Dental cleaning  
U rresale  
TB test  
Quarantine  
L (R) eye Results *None*

	Drug	Dosage
Pre-sedative		
Sedative	Telazol (4mg/kg)	0.21 0.22 mL [100mg/mL] IM
Antibiotic	Pen G (40,000 u/kg)	1mL [300,000 u/mL] IM

Weight: 6.6 Kg Heart Rate: 160 Temp: 103.7

Body Condition: Very Good Good Fair Poor

N	<u>ABN</u>	1. Integument	<i>hypertrophy left callosus</i>
<u>N</u>	ABN	2. Respiration	
<u>N</u>	ABN	3. Cardiovascular	
<u>N</u>	ABN	4. Gastrointestinal	
<u>N</u>	ABN	5. Urogenital	
<u>N</u>	ABN	6. Nervous	
<u>N</u>	ABN	7. Musculoskeletal	
<u>N</u>	ABN	8. Lymphatic	
<u>N</u>	ABN	9. Endocrine	
<u>N</u>	ABN	10. Special Senses	

Plan/Treatment: *Thyroid callosus*

Signature:

Date:

# Animal Morbidity Report

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 9/21/2001 Time 9:22:21 AM Initials DF Attitude Responsiveness Posture  
 Appetite Water Stool Urine  
 Consumption  
 MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

TB testi R. eye - neg.....  
 nail trim, dental cleaning.....  
 wt 6.6kg, HR 160, Temp 102.7.....  
 overall body condition very good, hypertrophy of left callous - trimmed.....

Plan

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 3/14/2002 Time 7:29:18 AM Initials DF Attitude Responsiveness Posture  
 Appetite Water Stool Urine  
 Consumption  
 MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight 7.2kg

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

TB tested R. eye.....  
 gave Telazol (3mg/kg), PenG (300,000u/kg).....  
 HR 200, temp 102.2, nail trim and dental cleaning, teeth look good, body condition good.....

Plan

PHYSICAL EXAM FORM

Date: 3-19-02 PI: M. Carroll Billing Name: Carroll Protocol: 0112A14081

Animal Information

Species: Rhesus ID#: 9711B Name: \_\_\_\_\_ Tattoo: 9711B 8 yrs old? Sex: F

6 mo TB test Clinical Presale Quarantine  
 Nail Trim Dental cleaning TB test (R) eye Results *hey*

	Drug	Dosage
7.2 kg Pre-sedative		
Sedative	Telazol (3mg/kg)	0.22 ml/s [100 mg/ml] IM
Antibiotic	Pen G (40,000 u/kg)	1 ml [300,000 u/ml] IM

Weight: 7.2 Heart Rate: 200 Temp: 102.2

Body Condition: Very Good Good Fair Poor

N	ABN	1. Integument	
N	ABN	2. Respiration	
N	ABN	3. Cardiovascular	
N	ABN	4. Gastrointestinal	teeth look good, slight staining
N	ABN	5. Urogenital	
N	ABN	6. Nervous	
N	ABN	7. Musculoskeletal	
N	ABN	8. Lymphatic	
N	ABN	9. Endocrine	
N	ABN	10. Special Senses	

Plan/Treatment:

Signature:

Date:

# Animal Morbidity Report

**Daily Observations:**

ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 3/19/2002 Time 9:39:20 AM Initials DF

Attitude

Responsiveness

Posture

Appetite Water Consumption Stool Urine

Temp. Pulse Resp. Pulse Character Resp. Character

MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude 
  Integument 
  Respiratory 
  Cardiovascular 
  Gastrointestinal 
  Musculoskeletal 
  Neurologic 
  Urogenital 
  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

TB test was negative

Plan

**Daily Observations:**

ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 9/19/2002 Time 7:42:29 AM Initials DF

Attitude

Responsiveness

Posture

Appetite Water Consumption Stool Urine

Temp. Pulse Resp. Pulse Character Resp. Character

MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight 7.4kg

Attitude 
  Integument 
  Respiratory 
  Cardiovascular 
  Gastrointestinal 
  Musculoskeletal 
  Neurologic 
  Urogenital 
  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

TB test R eye HR 198 T 101.9 TNT dental

body condition is very good L callous trimmed due to hypertrophy Telazol 0.36mls [100mg/ml] IM PenG 1mls [300000u/ml] IM

Plan

# Animal Morbidity Report

Daily Observations: ID 9711B Building Room:  Post-Op

Special Requests  Part. PO

Date 1/14/2003 Time 9:10:02 AM Initials Attitude Responsiveness Posture  General

Appetite Water Consumption Stool Urine

MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

Plan

Daily Observations: ID 9711B Building Room:  Post-Op

Special Requests  Part. PO

Date 3/12/2003 Time 10:29:30 AM Initials DF Attitude Responsiveness Posture  General

Appetite Water Consumption Stool Urine

MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight 7.5kg

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

TB test Left eye...TNT...dental cleaning...Telazol 0.23mls[3mg/ml] IM...PenG 1ml[300000u/ml] SQ...HR 150...Temp 100.5...body condition good...slight thinning on shoulders and arms...trimmed callous...staining on molars

Plan  
Day 1: red...TB test: negative  
Day 2: good  
Day 3: good

# Animal Morbidity Report

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 5/14/2003 Time 2:32:51 PM Initials DF Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
 MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

monkey escaped from the cage while the techs were trying to weigh the monkey. monkey was contained. several bruises starting on face around eyes. small amount of blood from the mouth. and a cut on the leg. (I did not see this cut but was told about by the tech) a glass flask was broken in the room.....

Plan group will give ibuprofen and will recheck first thing in the am.....

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 5/15/2003 Time 9:25:27 AM Initials DF Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
 MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

monkey appears to be doing well. face is bruised. temples are crusty. appears to be able to move easily.....

Plan will give ibuprofen today and tomorrow.....



# Animal Morbidity Report

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 5/20/2003 Time 10:43:54 AM Initials DF Attitude Responsiveness Posture  
Appetite Water Stool Urine  
Consumption  
MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

monkey appears to be doing well, alert and active, facial lesions are healing, small lesions are around temples.....

Plan  
will continue to monitor.....

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 5/26/200 Time 9:54:50 Initials DF Attitude Responsiveness Posture  
Appetite Water Stool Urine  
Consumption  
MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
Location  
Incision  
Condition

Progress Notes

NHP appears to be doing well, alert and active, lesions on face have healed.....

Plan  
will discharge case to vet.....

# Animal Morbidity Report

Daily Observations: ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 8/6/2003 Time 7:39:33 AM Initials SW

Attitude

Responsiveness

Posture

Appetite      Water Consumption      Stool      Urine

Temp.   Pulse   Resp.   Pulse Character   Resp. Character

MM Color      CRT (s)   Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude    Integument    Respiratory    Cardiovascular    Gastrointestinal    Musculoskeletal    Neurologic    Urogenital    Optic/Otic

Treatments Given:

Incision No./

Location

Incision

Condition

Progress Notes

Case discharged by veterinarian.....

Plan

Daily Observations: ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 9/29/2003 Time 9:35:59 AM Initials DF

Attitude

Responsiveness

Posture

Appetite      Water Consumption      Stool      Urine

Temp.   Pulse   Resp.   Pulse Character   Resp. Character

MM Color      CRT (s)   Hydration

Systems Exam (Check if Abnormal)

Current weight 7.6kg

Attitude    Integument    Respiratory    Cardiovascular    Gastrointestinal    Musculoskeletal    Neurologic    Urogenital    Optic/Otic

Treatments Given:

Incision No./

Location

Incision

Condition

Progress Notes

TB test right eye, gave Telazol 0.22mls [100mg/ml IM, PenG 1ml [300000units/ml] SQ, HR 200, temp 101.3, body condition is good, trimmed callous pads.....

Plan

Research Animal Resources, University of Minnesota  
**Animal Morbidity Report**

**Signalment:** ID 9711B Billing Name Carroll Protocol No. 0112A14081

Investigator Carroll Department Psychiatry Contact Jen Phone 6-6301  
 ID/Tattoo Species Strain Sex Age DOB DOA Incoming Wt. Vendor Final Disposition Date  
 Ruby Rhesus rhesus F Ad 11/12/97 4.65kg

**Master Problem List:**

No. Animals	Date Active	Resolved	Preventative Medicine	Date
			Semi-annual TB/dental/PE	3/22/2005
			Semi-annual TB/dental/PE	10/5/2004
			Semi-annual TB/dental/PE	4/12/2004
			Semi-annual TB/dental/PE	9/29/2003

**Master Treatment List:**

Dose	Rt.	Frequ.	Date Started	Completed	Lab Number	Necropsy No.
					D97-564	
					D98-362	

**Daily Observations:**

ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 9/3/2003 Time 8:01:49 AM Initials Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
 MM Color CRT (s) Hydration  
 Systems Exam (Check if Abnormal)

Current weight 7.4kg

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./ Location

Incision Condition

Progress Notes

Plan

PHYSICAL EXAM FORM

Date: \_\_\_\_\_ PI: Carroll Billing Name: Carroll Protocol: 0112A/4081

Animal Information

Species: RHESUS ID#: 9711B Name: \_\_\_\_\_ Tattoo: 9711B Sex: F

6 mo TB test Clinical  Presale Quarantine  
Nail Trim Dental cleaning TB test - L  R eye Results \_\_\_\_\_

	Drug	Dosage
<u>7.5 kg</u> Pre sedative		
Sedative	<u>Telazol (3mg/kg)</u>	<u>0.23mL [100mg/mL] IM</u>
Antibiotic	<u>Pen G (40,000u/kg)</u>	<u>1mL [300,000u/mL] SQ</u>

Weight: 7.4 kg Heart Rate: 198 Temp: 101.9

Body Condition: Very Good Good Fair Poor

N	ABN	1. Integument	<u>Trimmed left callous.</u>
N	ABN	2. Respiration	
N	ABN	3. Cardiovascular	
N	ABN	4. Gastrointestinal	
N	ABN	5. Urogenital	
N	ABN	6. Nervous	
N	ABN	7. Musculoskeletal	
N	ABN	8. Lymphatic	
N	ABN	9. Endocrine	
N	ABN	10. Special Senses	

Plan/Treatment: \_\_\_\_\_

Signature: M. B...

Date: \_\_\_\_\_

PHYSICAL EXAM FORM

Date: \_\_\_\_\_ PI: M. Carroll Billing Name: Carroll Protocol: 0112A14081

Animal Information  
 Species: Rhesus ID#: 9711B Name: \_\_\_\_\_ Tattoo: 9711B Sex: JF

6 mo TB test Nail Trim Clinical Dental cleaning  resale  Quarantine  
 TB test  L  R eye Results \_\_\_\_\_

Weight	Drug	Dosage
<u>7.5 kg</u>		
Pre-sedative		
Sedative	<u>Telazolil (3mg/kg)</u>	<u>0.23ml [100mg/ml] 1ml</u>
Antibiotic	<u>PenH (40,000u/kg)</u>	<u>1ml [300000u/ml] 1ml</u>

Weight: 7.5 Heart Rate: 150 Temp: 100.5

Body Condition:  Very Good  Good  Fair  Poor

N	ABN	System	Findings
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	1. Integument	<u>slight thinning on arms, <sup>shoulders</sup>rimmed callous</u>
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	2. Respiration	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	3. Cardiovascular	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	4. Gastrointestinal	<u>staining on molars</u>
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	5. Urogenital	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	6. Nervous	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	7. Musculoskeletal	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	8. Lymphatic	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	9. Endocrine	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	10. Special Senses	

Plan/Treatment: ✓ - Day 1 - red  
Day 2 - good  
Day 3 - good

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

PHYSICAL EXAM FORM

Date: 9/29/03 PI: Carroll Billing Name: Carroll Protocol: 0112A14081

Animal Information

Species: Rhesus ID#: 9711B Name: Tattoo: 9711B 5+4rs Sex: F

6 mo TB test Clinical / Presale Quarantine  
 Nail Trim Dental cleaning TB test - L (R) eye Results NEG

Weight	Drug	Dosage
7.4kg		
Pre-sedative		
Sedative	Telazol (3mg/kg)	0.22 mL [100mg/mL] IM
Antibiotic	Pen G (40,000 U/kg)	1 mL [300,000 U/mL] SQ

Weight: 7.6kg Heart Rate: 200 Temp: 101.3

Body Condition: Very Good Good Fair Poor

N	<u>ABN</u>	1. Integument	trimmed callouses
<u>N</u>	ABN	2. Respiration	
<u>N</u>	ABN	3. Cardiovascular	
<u>N</u>	ABN	4. Gastrointestinal	
<u>N</u>	ABN	5. Urogenital	
<u>N</u>	ABN	6. Nervous	
<u>N</u>	ABN	7. Musculoskeletal	
<u>N</u>	ABN	8. Lymphatic	
<u>N</u>	ABN	9. Endocrine	
<u>N</u>	ABN	10. Special Senses	

Plan/Treatment:

*[Handwritten Signature]*

Signature:

Date: 10/3/03

# Animal Morbidity Report

**Daily Observations:**

ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 9/30/2003 Time 6:56:01 AM Initials DF

Attitude

Responsiveness

Posture

Appetite

Water Consumption

Stool

Urine

Temp.

Pulse

Resp.

Pulse Character

Resp. Character

MM Color

CRT (s)

Hydration

Systems Exam (Check if Abnormal)

Current weight

- Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./

Location

Incision

Condition

Progress Notes

eyelid looks good

Plan

**Daily Observations:**

ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 10/1/2003 Time 7:03:28 AM Initials DF

Attitude

Responsiveness

Posture

Appetite

Water Consumption

Stool

Urine

Temp.

Pulse

Resp.

Pulse Character

Resp. Character

MM Color

CRT (s)

Hydration

Systems Exam (Check if Abnormal)

Current weight

- Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./

Location

Incision

Condition

Progress Notes

eyelid is good

Plan

# Animal Morbidity Report

Daily Observations: ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 10/28/2003 Time 9:50:44 AM Initials DF

Attitude

Responsiveness

Posture

Appetite Water Consumption Stool Urine

Temp. Pulse Resp. Pulse Character Resp. Character

MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./ Location

Incision Condition

Progress Notes

NHP was moved to the bottom cage below ..... appears to be not transitioning well. NHP is reluctant to come to the front of the cage. does not appear as social since moving.....

Plan will continue to monitor.....

Daily Observations: ID 9711B

Building

Room:

- Post-Op
- Part. PO
- General

Special Requests

Date 12/4/2003 Time 8:05:58 AM Initials DF

Attitude

Responsiveness

Posture

Appetite Water Consumption Stool Urine

Temp. Pulse Resp. Pulse Character Resp. Character

MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight 7.2kg

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./ Location

Incision Condition

Progress Notes

Plan



# Animal Morbidity Report

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 10/2/2003 Time 2:50:13 PM Initials DF Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
 MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

eyelid looks good

Plan  
TB test negative

Daily Observations: ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 4/6/2004 Time 8:56:01 Initials DF Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine Temp. Pulse Resp. Pulse Character Resp. Character  
 MM Color CRT (s) Hydration

Systems Exam (Check if Abnormal)

Current weight 7.9kg

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic

Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

TB test left eye, nail trim, dental cleaning, sedated with Telazol 0.22mls [100mg/ml] IM, HR 200, Temp. 103.1, body condition very good, menses

Plan  
will continue to monitor

PHYSICAL EXAM FORM

Date: 4/16/04 PI: Carroll Billing Name: Carroll Protocol: 0112A14081

Animal Information

Species: Rhesus ID#: 9711B Name: Tattoo: 9711B Sex: ♂

6 mo TB test Clinical Presale Quarantine  
 Nail Trim Dental cleaning TB test (L) R eye Results: NED


Drug	Dosage
7.6 kg Pre-sedative	
Sedative Telazol (3mg/kg)	0.22mls [100mg/ml] IM 2
Antibiotic PenG (40,000 U/kg)	1 ml [300,000u/ml] IM

Weight: 7.9 kg Heart Rate: 200 Temp: 103.1

Body Condition: Very Good Good Fair Poor

(N)	ABN	1. Integument	
(N)	ABN	2. Respiration	
(N)	ABN	3. Cardiovascular	
(N)	ABN	4. Gastrointestinal	
(N)	ABN	5. Urogenital	menses
(N)	ABN	6. Nervous	
(N)	ABN	7. Musculoskeletal	
(N)	ABN	8. Lymphatic	
(N)	ABN	9. Endocrine	
(N)	ABN	10. Special Senses	

Plan/Treatment: keep up tattoos

Signature: 

Date: 4/16/04

# Animal Morbidity Report

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 4/7/2004 Time 9:01:33 AM Initials DF Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine  
 MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

eyelid looks good, no swelling or redness

Plan  
will continue to monitor

**Daily Observations:** ID 9711B Building Room:  Post-Op  
 Part. PO  
 General

Special Requests

Date 4/8/2004 Time 9:01:41 Initials DF Attitude Responsiveness Posture  
 Appetite Water Consumption Stool Urine  
 MM Color CRT (s) Hydration Temp. Pulse Resp. Pulse Character Resp. Character

Systems Exam (Check if Abnormal)

Current weight

Attitude  Integument  Respiratory  Cardiovascular  Gastrointestinal  Musculoskeletal  Neurologic  Urogenital  Optic/Otic  
 Treatments Given:

Incision No./  
 Location  
 Incision  
 Condition

Progress Notes

eyelid looks good, no swelling or redness

Plan  
will continue to monitor